Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Akeso, Inc. is conducting a Phase I clinical study titled ‘A Phase I ...
Agios Pharmaceuticals (($AGIO)) announced an update on their ongoing clinical study. Agios Pharmaceuticals has initiated a Phase 1 clinical trial ...
About BMF-650 BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity. Related to the broader orforglipron chemotype, ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class ...
SCYNEXIS Inc. (NASDAQ: SCYX) is one of the best long term penny stocks with huge upside potential. On September 30, SCYNEXIS ...
Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and ...
Among trial phases, Phase 1 dominates the early phase clinical trial outsourcing market, accounting for 45.6% of revenue in ...
CuraSen Therapeutics has commenced its Phase IIa proof-of-concept trial of CuraAX (CST-3056) with dosing of the first patient ...
Arcturus Therapeutics Holdings Inc. faces a solid cash runway into 2028, pipeline setbacks, and risk/reward profile. Learn ...
Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q3 2025 Earnings Call October 22, 2025 4:30 PM EDT Welcome to the Viking Therapeutics Third Quarter 2025 Financial Results Conference Call. [Operator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback